In cardiac surgery with cardiopulmonary bypass (CPB), excessive blood loss requiring the transfusion of multiple red blood cell (RBC) units is a common complication that is associated with significant morbidity and mortality. The objective of this study was to develop a prediction rule for massive blood transfusion (MBT) that could be used to optimize the management of, and research on, at-risk patients.
Objectif : En cardiochirurgie avec circulation extracorporelle (CEC), une perte de sang excessive exigeant la transfusion de multiples unités de culots globulaires (CG) est une complication fréquente associée à une morbidité et à une mortalité significatives. L'objectif de notre étude était d'élaborer une règle de prédic-tion pour la transfusion massive (TM) qui pourrait être utilisée pour optimaliser la recherche sur les patients à risque, et leur traitement.

Méthode : Les données prospectives ont été recueillies sur les patients qui ont subi une opération avec CEC dans un hôpital entre 2000 et 2005. Les patients ayant reçu ≥ cinq unités de CG en moins d'un jour postopératoire ont été classés comme TM. La régression logistique a permis de choisir et pondérer convenablement les variables périopératoires de la règle de prédiction qui a été élaborée d'après les premiers 60 % de l'échantillon et validée sur les 40 % restant.
Résultats : Des 10 667 patients inclus, 925 (8,7 %) E XCESSIVE blood loss necessitating the transfusion of multiple units of red blood cells (RBC) is a relatively common complication of cardiac surgery that is independently associated with serious postoperative adverse events including sepsis, acute respiratory distress syndrome, renal failure, and death. [1] [2] [3] [4] A clinical prediction rule that could accurately estimate the probability of massive blood transfusion (MBT) after cardiac surgery would have clinical and research relevance. Such a prediction rule could be used to rationalize clinical management by, for example, limiting the use of expensive blood conservation modalities (such as aprotinin or cell salvage and washing) in patients identified as being at low-risk for MBT. It could also be used to investigate, and, if found to be appropriate, institute preventive measures (such as modifying risk factors or prophylactic administration of hemostatic agents or coagulation factors) to reduce the risk of MBT in those identified as being at high-risk for MBT.
Previous studies have identified several variables that are associated with RBC transfusion or excessive blood loss in cardiac surgery (Table I) . 2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] However, no multivariable prediction rules have been developed that can be used by clinicians to accurately estimate the probability of MBT in cardiac surgical patients. Consequently, we sought to develop and validate such a prediction rule in a cohort of patients who underwent cardiac surgery with cardiopulmonary bypass (CPB) at a single institution.
Methods
Patient population and data collection
Following institutional ethics approval, data on consecutive patients who underwent cardiac surgery with CPB at the Toronto General Hospital from January 2000 to May 2005 were obtained from prospectively collected databases that have been previously described. 4, 22 Full-time research personnel blinded to the details of this current study adjudicated all patient outcomes included in the databases. Quality assurance checks of the databases have consistently revealed a missing data rate of less than 2% and an error rate of less than 2%. For this study, patients with missing data that could not be obtained from their hospital records were excluded from the analyses. For patients who underwent more than one cardiac operation with CPB at the study institution during the study period, only their first surgery was used in the analyses.
Clinical practice
Hemostatic and CPB management during the study period were as follows. Antifibrinolytics [tranexamic acid (Cyclokapron®, Pharmacia & UpJohn Inc., Mississauga, ON, Canada) 50 to 100 mg·kg -1 or aprotinin (Trasylol®, Bayer AG, Toronto, ON, Canada) 6 x 10
6 units] were routinely administered to all patients. Institutional guidelines recommended that aprotinin be reserved for patients who had active endocarditis, were undergoing complex procedures requiring prolonged CPB support, or had at least two previous sternotomies. Anticoagulation for CPB was achieved with heparin to maintain an activated clotting time above 480 sec. The CPB circuit (non-heparin coated; membrane, hollow fibre oxygenator; roller pump) was primed with 1.8 L of Ringer's lactate and 50 mL of 20% mannitol. Albumin (5% or 25%) and synthetic colloids (Pentaspan®; Bristol-Myers Squibb, Montreal, QC, Canada) were used at the discretion of the clinical team. Management of CPB included systemic temperature drift to 34°C, alpha-stat pH management, targeted mean perfusion pressure between 50-70 mmHg, and pump flow rates of 2.0-2.4 L·min
Myocardial protection was achieved with intermittent antegrade and, occasionally, retrograde blood cardioplegia. When necessary, deep hypothermic circulatory arrest (DHCA) was achieved by cooling to 20-28°C, depending on the anticipated duration of circulatory arrest. Neuroprotection was carried out with antegrade or retrograde cerebral perfusion at the discretion of the operating surgeon. When circulatory arrest was carried out for very short periods of time, cerebral perfusion was often omitted. Pericardial blood was salvaged into the cardiotomy suction reservoir and re-infused via the CPB circuit for as long as patients were anticoagulated. After separation from CPB, heparin was neutralized with protamine sulphate to a target activated clotting time within 10% of baseline.
Perioperative blood management during the study period was as follows. To guide RBC transfusions, hematocrit concentrations were measured before surgery, before CPB, every 15 min during CPB, every 30 min after CPB in the operating room, upon arrival and every four hours thereafter in the intensive care unit for the first 24 hr after surgery (and more frequently in bleeding or unstable patients). Leukoreduced RBC concentrates were transfused to maintain the hematocrit concentration at or above 18-20% during CPB, and at or above 24-27% after CPB.
Platelet counts, partial thromboplastin time, prothrombin time and international normalized ratio (INR) were routinely measured before surgery and upon arrival to the intensive care unit after surgery. During surgery, these tests were performed at the discretion of the clinical team in patients with prolonged CPB or microvascular hemorrhage following termination of CPB and neutralization of heparin. Indications for platelet transfusion included a platelet count of < 50 x 10 , or ongoing hemorrhage after prolonged CPB (> two hours was considered prolonged by most clinicians) irrespective of platelet counts. In cases where the risk of developing a qualitative platelet disorder after CPB was deemed to be high (e.g., recent use of long-acting platelet glycoprotein IIb/IIIa receptor antagonist therapy, high-dose clopidogrel, or CPB > three hours), platelets were at times transfused prophylactically upon termination of CPB. All platelets (random donor or single donor) were leukoreduced by the Canadian Blood Services. Fresh frozen plasma was transfused to bleeding patients if the INR was greater than 1.5 after complete neutralization of heparin with protamine. Owing to 30 min turnaround times for coagulation tests, fresh frozen plasma and platelets were at times transfused empirically in bleeding patients. Cryoprecipitate transfusion was guided by fibrinogen levels, which were measured in bleeding patients. Patients received eight units of cryoprecipitate if their fibrinogen level was less than 1 g·L -1 . Not applicable RBC = red blood cells; NYHA = New York Heart Association; INR = international normalized ratio; CPB = cardiopulmonary bypass.
Changes in blood management
with excessive, refractory hemorrhage after cardiac surgery was introduced at our institution, the details of which have been described previously. 23 In January 2003, the processing times for blood gas and hematocrit measures were reduced to two to five minutes from ten to 15 min owing to the introduction of a point-of-care system. Finally, throughout the study period there was a gradual increase in the RBC transfusion trigger during CPB, likely as a result of our observations that hematocrit concentrations below 20% were associated with increased morbidity.
22,24
Dependent and predictor variables
The primary definition for MBT was ≥ five units of RBC transfused within one day of surgery. This cutoff was based on the distribution of perioperative RBC transfusion in our patient population (corresponding to the 90th percentile) as well as on the independent relationship between the number of units of RBC transfused and adverse postoperative events. 4 To explore the predictive value of clinical variables associated with greater blood loss, a second classification for MBT using a cutoff of ≥ seven units of RBC within one day of surgery (95th percentile) was also assessed.
Predictor variables included perioperative variables previously shown to be associated with perioperative blood loss (Table I) , as well as several variables related to adverse postoperative outcomes.
Statistical analyses SAS™ version 8.2 (SAS Institute, Inc., Cary, NC, USA) was used for the statistical analyses. Categorical variables were summarized as frequencies and percentages, continuous variables as means and standard deviations if normally distributed, and medians and interquartile ranges if not normally distributed.
Patients operated on from January 2000 to December 2002 were used for model development (training set) and those operated on from January 2003 to May 2005 were used for model validation (validation set). January 2003 was used as the cutoff because it correlated with the changes of practice noted above and was therefore anticipated to result in training and validation sets that would differ from each other, allowing for a more robust test of the validity of the model. Characteristics of the two groups were compared using the t-test or Wilcoxon rank sum test for continuous variables and the Chi-square test for categorical variables.
Multivariable logistic regression was used to appropriately select and weigh the predictor variables for inclusion in the prediction rule. 25 Bivariate analysis (using the Chi-square test for categorical variables and the t-test or Wilcoxon rank-sum test for continuous variables) was first carried out to assess the unadjusted relationship between the predictor variables and MBT in the training set. The shape of the relationships between the continuous predictor variables and MBT (logit transformation) were assessed using restricted cubic spline functions. 25 Based on this analysis, some variables were either mathematically transformed or categorized for the logistic regression analysis. 25 Backward stepwise logistic regression modelling was then carried out to construct the model for the prediction rule. All significant (P < 0.1) predictor variables were considered for inclusion in the model. Variable retention in the model was guided by the variables' Wald χ 2 statistic and co-linearity and interaction issues. 25 For comparison, a second model was constructed using the second cutoff of ≥ seven units of RBC as the dependent variable, using similar modelling steps. The models' calibration was assessed by the Hosmer-Lemeshow goodness-of-fit test (the larger the P value, the better the fit), and discriminative ability was assessed by the c-index [which is equivalent to the area under the receiver operating characteristic (ROC) curve]. 25 Based on the performance of the primary model (≥ five units of RBC) at various probability cutoffs, optimal cutoffs were identified for classifying patients as being at low, moderate, or high-risk for MBT. Since application of logistic regression models involves complex calculations, a simple risk score was developed by categorizing all continuous variables in the prediction rule based on the shape of their spline function in the logistic regression analysis, and assigning a risk derived from the β coefficients of the variables in the logistic regression model. The predictive accuracy of the prediction rule and the simplified risk score were assessed in the validation set.
Data and medical records of a sample (identified randomly based on date of surgery) of patients who had MBT, but were misclassified by the prediction rule as low-risk, were reviewed to obtain the reasons for excessive blood loss.
Results
A total of 10,667 patients who underwent cardiac surgery with CPB during the study period were included in the analysis (< 1% of cases were deleted due to missing variables). Overall, 925 (8.7%) and 470 (4.4%) patients received ≥ five and ≥ seven RBC units within one day of surgery, respectively (Table II) . A total of 6,651 consecutive patients were assigned to the training set and the remaining 4,016 patients were assigned to the validation set. The training and valida- tion sets had important differences including a higher incidence of MBT (≥ 5 U: 11% vs 7%; P < 0.0001) and procedures other than isolated coronary artery bypass grafting or single valve (34% vs 25%; P < 0.0001) in the validation set (Table III) .
The bivariate (unadjusted) relationships between the predictor variables and MBT (≥ five units) in the training set are shown in Table IV . The shapes of the relationships between some of the continuous variables and MBT are shown in Figure 1 . Several continuous variables were categorized to conform to the linearity assumption of logistic regression or to simplify the model. The logistic regression model for MBT (≥ five units) is shown in Table Va . The model was well calibrated (Hosmer-Lemeshow goodness-of-fit P = 0.2) and discriminative (c-index = 0.88) when tested on the patients in the training set. Table Vb shows the model for the secondary MBT definition (≥ 7 U). The second model was also well calibrated (HosmerLemeshow goodness-of-fit P = 0.3) and discriminative (c-index = 0.90) when tested on the patients in the training set. Moreover, the same variables were retained in the two models with little change in their predictive odds ratios. Notably, variables related to perioperative hemodilution (body surface area, preoperative hemoglobin, and nadir CPB hematocrit) remained in this second model, albeit their predictive value (as measured by their Wald χ 2 ) was reduced. Table VI lists the sensitivity, specificity, and positive and negative predictive values of the primary model when it was re-applied to the patients in the training set using various probability cutoffs. The same data are provided as a ROC curve in Figure 2 . The 0.10 and 0.35 probability levels were selected as the optimal probability cutoffs for classifying patients into low-, moderate-, and high-risk groups. Table VII shows the risk score that was developed based on the β coefficients of the variables in the primary model. The risk score is additive and can range from 0 to 14. Risk classification cutoffs were based on the 75th percentile (2.5) and 95th percentile (4.5) scores to correspond with the cutoffs of the predic- Table VIII shows the performance of the prediction rule and the risk score in the validation set. For comparison, the predictive accuracies of three clinical variables known to be important predictors for excessive blood loss are also shown in Table VIII .
Of the 74 patients in the validation set misclassified as high-risk by the prediction rule, 41 received four units, 16 received three units, and the remainder received less than three units of RBC within one day of surgery. Of the 157 misclassified low-risk patients, 62 received five units, 24 received six units, 19 received seven units, and the remainder received more than seven units of RBC within one day of surgery. To identify the reasons for misclassification of low-risk patients, 50 of them were randomly selected and reviewed in detail. Of these 50 patients, 15 (30%) had surgical bleeding, eight (16%) had received antiplatelet or anticoagulant medications up to the time of surgery, and 27 (54%) had no identifiable reasons for MBT.
Discussion
Although the definition of excessive blood loss varies from study to study, 26 a consistent finding amongst studies is that cardiac surgical patients who bleed excessively and require MBT are at increased risk for serious adverse events. 2, 4, [15] [16] [17] 21, 26 The clinical prediction rule developed in this study provides several opportunities for improving the outcome of patients at risk for MBT. First, having identified the relative importance of predictors of MBT, some of which are modifiable, it may be possible to reduce patients' underlying risk by altering these variables. Second, by providing accurate risk estimates for MBT before termination of CPB, the prediction rule can be used to prepare for and institute early and aggressive therapy for bleeding in those identified as being at high-risk. Third, the prediction rule can be used to investigate, and, if found to be appropriate, institute prophylactic therapies (such as hemostatic agents) 27 to reduce the risk of MBT in high-risk patients.
Definition of MBT
The primary definition of MBT in this study was the transfusion of at least five units of RBC within one day of surgery. We have previously shown that this threshold, which occurs in only about 10% of our patients, is independently associated with significant increase in mortality. 4 A second threshold of ≥ seven units of RBC within one day of surgery, corresponding to the 95th percentile in our patient population, was also analyzed. That the logistic regression models for the two outcomes were very similar supports the robustness of the prediction rule.
As a surrogate measure for perioperative blood loss, there are limitations with using units of RBC transfused perioperatively. Since RBC transfusions are based on factors other than perioperative blood loss, such as patients' baseline red blood cell volume and clinicians' transfusion practice, one cannot assume that every patient who was categorized as MBT had excessive perioperative blood loss. Owing to the high RBC transfusion thresholds used for defining MBT, however, it is reasonable to assume that few patients categorized as having had MBT did not have excessive perioperative blood loss.
Other measures of perioperative blood loss have their own limitations. Clinical estimates of blood loss are inherently unreliable, even under controlled conditions. 28 Others have used surgical re-exploration as the criteria for excessive blood loss. 2, 16, 17, 21 Many patients with excessive blood loss, however, never require re-exploration, and some patients undergo reexploration for causes other than bleeding. In cardiac surgery, the amount of blood in mediastinal tubes can also be used to identify excessive blood loss. 15 This method, however, does not capture the significant proportion of patients who bleed excessively in the operating room after termination of CPB. 
Independent predictors of MBT as identified by the prediction rule and risk modification opportunities
Massive blood transfusion after cardiac surgery can be due to surgical or non-surgical (i.e., coagulopathy) causes. Surgical bleeding is estimated to account for about 50% of cases that require re-exploration. 29 In our sample, about one-third of patients with MBT required re-exploration (344/925). Although surgical bleeding is often unpredictable, the prediction rule included several variables that may be associated with increased risk of surgical bleeding owing to increased surgical complexity. These were type of procedure, urgency of procedure, previous sternotomy, CPB duration, and DHCA. Interestingly, when the surgeon was analyzed as a dichotomous variable based on the MBT median rate, it only had a moderate influence on the risk of MBT. Analyzing each surgeon separately increased the overall importance of the variable in the model but did not alter the discriminative ability or predictive performance of the model (results not shown).
The causes of coagulopathy after cardiac surgery with CPB include platelet-related abnormalities owing to thrombocytopenia or platelet dysfunction, reduction in plasma coagulation factors owing to hemodilution, excessive primary or secondary [due to disseminated intravascular coagulation (DIC)] fibrinolysis, and relative protamine deficiency or excess. 26, 30 Excessive primary fibrinolysis is unlikely to be a factor in subjects in this study due to the routine use of antifibrinolytics in nearly all patients. Since heparin and protamine doses were not captured in the databases, their predictive value could not be assessed. Not surprisingly, variables associated with platelet-related coagulopathy were the most predictive variables in the prediction rule. Of these, the most important was CPB duration, which is known to cause a progressive impairment in platelet function. 29, 31 Consistent with this, we found a linear relationship between CPB duration and risk of MBT (Figure 1 ). Deep hypothermic circulatory arrest, which not only prolongs CPB duration but also has detrimental effects on platelet function that are additive to those of CPB, 32 was also an important predictor of MBT. Another important predictor was pre-existing thrombocytopenia, with the risk most pronounced when platelet counts were less than 100 x 10 9 ·L -1 . Low platelet count has been found to be associated with MBT after cardiac surgery in some, 33 but not all, 30 previous studies. Our findings support the opinion of some experts that cardiac surgical patients at high-risk for MBT may benefit from platelet transfusions if their platelet count is less than 100 risk for MBT. This information can then be used to reduce costs in the low-risk group by, for example, limiting the use of expensive blood conservation modalities (such as aprotinin or cell salvage and washing), and to reduce the risk of MBT in the high-risk group by, for example, instituting preventive measures (such as reducing hemodilution or prophylactic administration of hemostatic agents).
Limitations of the prediction rule and future direction
Owing to lack of data, we could not assess the predictive value of potentially important variables such as preoperative drugs [except for heparin, coumadin (through measurement of INR), and ASA] and use of synthetic colloids. 37 Future studies are required to delineate the effects of these factors on MBT.
Owing to institutional variations in transfusion practice, 6 our prediction rule may not be valid at other institutions. The prediction rule, however, did perform well in the validation set, even though patients in the validation set differed from those in the training set on several important variables such as date of surgery and case-mix. Moreover, the variables included in the prediction rule are not site-specific; the same variables have been found to be associated with blood loss in other studies. Although these factors suggest that the prediction rule should be externally generalizable, it needs to be assessed at other institutions.
Future studies are also needed to assess the clinical utility of the prediction rule. Moreover, owing to the low predictive accuracy of the prediction rule in the moderate-risk group, there is a need to investigate strategies that may improve its predictive ability in this group, such as point-of-care coagulation testing prior to termination of CPB. 38 Finally, it is important to determine why some patients with no clinical risk factors for MBT nevertheless bleed excessively after cardiac surgery. A potentially important area of investigation in these patients is the role of genotype in bleeding. 39 In summary, we developed and internally validated a prediction rule (and a simple risk score) that can accurately predict the risk of MBT in the majority of cardiac surgical patients. Future studies are required to refine the predictive ability of the prediction rule and to assess its external generalizability and clinical utility. 290 (9%) 3327 * CPB < 120 min = low-risk; 120 -150 min = moderate-risk; and > 150 min = high-risk †first-time + (elective or semi-urgent) = low-risk; redo + (elective or semi-urgent) = moderate-risk; urgent or emergent = high-risk. CPB = cardiopulmonary bypass; MBT = massive blood transfusion.
